Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Journal of Cardiac Failure · 2025-03 · 31 (3) · 525-533
DOI: 10.1016/j.cardfail.2024.06.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2025-03. Verfasst von Pablo Garcia-Pavia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain; Universidad Francisco de Vitoria, Pozuelo de Alarcon, Spain; C…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles, Cardiomyopathies. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
BACKGROUND: In the pivotal Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality rates, leading to its approval in many countries for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Real-world evidence on survival in patients with ATTR-CM following tafamidis treatment has not been extensively reported. METHODS AND RESULTS: The Transthyretin Amyloidosis Outcomes Survey (THAOS) was a longitudinal, observational, phase 4 study of patients with transthyretin amyloidosis and asymptomatic participants carrying pathogenic transthyretin variants. Patients from THAOS with a predominantly cardiac phenotype at enrollment were included, and survival was analyzed according to tafamidis treatment status (treated or untreated). Results are based on the completed THAOS dataset. In tafamidis-treated (n = 587) and tafamidis-untreated (n = 854) patients, respectively, median age at enrollment was 77.7 and 76.4 years, 91.8% and 90.0% were male, and 91.8% and 83.8% had wild-type disease. Survival rates (95% CI) at 30 and 42 months, respectively, were 84.4% (80.5-87.7) and 76.8% (70.9-81.7) in tafamidis-treated patients, and 70.0% (66.4-73.2) and 59.3% (55.2-63.0) in tafamidis-untreated patients. Survival rates in genotype subgroups (wild-type and variant) were similar to those of the overall cohort. Survival rates were better in a contemporary cohort, as reflected by a sensitivity analysis performed in patients enrolled after vs before 2019. No new safety signals were identified. CONCLUSIONS: In this real-world cohort of patients with ATTR-CM, survival rates were higher than in ATTR-ACT and consistent with more recent reports, suggesting early diagnosis and treatment with tafamidis has improved life expectancy in ATTR-CM. These results provide further evidence supporting tafamidis' safety and effectiveness. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00628745.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain; Universidad Francisco de Vitoria, Pozuelo de Alarcon, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spa…
- Department of Cardiology, Angiology, and Respiratory Medicine, Medical University of Heidelberg, Heidelberg, Germany.
- University of Pennsylvania Health System, Philadelphia, PA, USA.
- Pfizer Inc, New York, NY.
- Columbia University College of Physicians and Surgeons, New York, NY, USA.
Förderung
- Pfizer Inc
Zitieren
APA
Garcia-Pavia, P., Kristen, A. V., Drachman, B., Carlsson, M., Amass, L., Angeli, F. S., Maurer, M. S., & THAOS investigators (2025). Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS). Journal of Cardiac Failure, 31(3), 525-533. https://doi.org/10.1016/j.cardfail.2024.06.003
Vancouver
Garcia-Pavia P, Kristen AV, Drachman B, Carlsson M, Amass L, Angeli FS, et al. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS). Journal of Cardiac Failure. 2025;31(3):525-533. doi:10.1016/j.cardfail.2024.06.003
BibTeX
@article{GarciaPavia2025,
author = {Garcia-Pavia, Pablo and Kristen, Arnt V and Drachman, Brian and Carlsson, Martin and Amass, Leslie and Angeli, Franca Stedile and Maurer, Mathew S and THAOS investigators, THAOS investigators},
title = {Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)},
journal = {Journal of Cardiac Failure},
year = {2025},
volume = {31},
number = {3},
pages = {525--533},
doi = {10.1016/j.cardfail.2024.06.003}
}
EUVIMED